{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:43:31Z","timestamp":1791333811757,"version":"4.3.1"},"reference-count":76,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universitas Padjadjaran"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Japanese Encephalitis (JE) is a mosquito-borne viral infection that causes acute brain inflammation. First identified in Japan in 1871, the disease gained renewed global attention in 2025 after emerging in a non-endemic region, raising significant healthcare concerns. Vaccination remains the most effective strategy for preventing outbreaks. However, low- and middle-income countries (LMICs) face considerable challenges in implementing vaccination programs due to geographical, economic, and regulatory barriers. Most existing studies on JE vaccines (JEVs) have been conducted in higher-income countries, leaving critical gaps in data on efficacy and safety in LMIC settings. Furthermore, uncertainties surrounding cost-effectiveness make funding decisions more complex. This narrative review evaluates the current evidence on JE vaccination in LMICs, based on a literature search in PubMed and ScienceDirect covering 2005\u20132025. The review examines vaccine efficacy, safety, cost-effectiveness, and policy implementation. Findings show that JEVs demonstrate high efficacy and strong safety profiles, with mild adverse effects, most commonly fever. The live attenuated SA 14-14-2 vaccine (LAJEV) is particularly cost-effective, offering substantial economic benefits by reducing healthcare expenditures in endemic regions. To ensure sustainability, vaccination programs in LMICs require tailored policies and targeted financial support. Policy frameworks must be adapted to local contexts, enabling focused, effective, and equitable implementation.<\/jats:p>","DOI":"10.3390\/vaccines13101038","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:56:29Z","timestamp":1759996589000},"page":"1038","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Japanese Encephalitis Vaccine in Low- and Middle-Income Countries (LMICs): A Narrative Review of Efficacy, Effectiveness, Safety, Cost, and Policy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4974-8000","authenticated-orcid":false,"given":"Eufrasia Ine","family":"Pilihanto","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8342-2870","authenticated-orcid":false,"given":"Btari Kalisha","family":"Nyratri","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Dafrizal","family":"Firdaus","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-0482","authenticated-orcid":false,"given":"Rano Kurnia","family":"Sinuraya","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, West Java, Indonesia"},{"name":"Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung 40132, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","first-page":"48","article-title":"Review Article Japanese Encephalitis: A Clinical Review","volume":"26","author":"Haque","year":"2025","journal-title":"J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.20506\/rst.34.2.2370","article-title":"Japanese encephalitis","volume":"34","author":"Morita","year":"2015","journal-title":"Rev. Sci. Tech."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/14712598.8.1.95","article-title":"Current use and development of vaccines for Japanese encephalitis","volume":"8","author":"Beasley","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pneurobio.2010.01.008","article-title":"Overview: Japanese encephalitis","volume":"91","author":"Misra","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: Alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/hv.26902","article-title":"Japanese encephalitis","volume":"10","author":"Yun","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pegu, S.R., Das, P.J., Sonowal, J., Sengar, G.S., Deb, R., Yadav, A.K., Rajkhowa, S., Choudhury, M., Gulati, B.R., and Gupta, V.K. (2023). Japanese Encephalitis Virus Genotype III Strains Detection and Genome Sequencing from Indian Pig and Mosquito Vector. Vaccines, 11.","DOI":"10.3390\/vaccines11010150"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2343910","DOI":"10.1080\/22221751.2024.2343910","article-title":"Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus","volume":"13","author":"Kim","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Xu, G., Gao, T., Wang, Z., Zhang, J., Cui, B., Shen, X., Zhou, A., Zhang, Y., Zhao, J., and Liu, H. (2023). Re-Emerged Genotype IV of Japanese Encephalitis Virus Is the Youngest Virus in Evolution. Viruses, 15.","DOI":"10.3390\/v15030626"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4269\/ajtmh.23-0036","article-title":"Japanese Encephalitis among Adults: A Review","volume":"108","author":"Hills","year":"2023","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Preedy, V.R., and Watson, R.R. (2010). Measuring Japanese Encephalitis (JE) Disease Burden in Asia. Handbook of Disease Burdens and Quality of Life Measures, Springer.","DOI":"10.1007\/978-0-387-78665-0"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4269\/ajtmh.17-0054","article-title":"Clinical Characteristics of Severe Japanese Encephalitis: A Case Series from South Korea","volume":"97","author":"Sunwoo","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, H.Y., Yang, C.Y., Hsieh, C.Y., Yeh, C.Y., Chen, C.C., Chen, Y.C., Lai, C.C., Harris, R.C., Ou, H.T., and Ko, N.Y. (2021). Long-term neurological and healthcare burden of adults with Japanese encephalitis: A nationwide study 2000-2015. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009703"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/JVI.77.5.3091-3098.2003","article-title":"Origin and evolution of Japanese encephalitis virus in southeast Asia","volume":"77","author":"Solomon","year":"2003","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100879","DOI":"10.1016\/j.onehlt.2024.100879","article-title":"Revisiting the risk of introduction of Japanese encephalitis virus (JEV) into the United States\u2014An updated semi-quantitative risk assessment","volume":"19","author":"Dixon","year":"2024","journal-title":"One Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/vbz.2018.2291","article-title":"Changing Geographic Distribution of Japanese Encephalitis Virus Genotypes, 1935\u20132017","volume":"19","author":"Gao","year":"2019","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid1501.080311","article-title":"Past, present, and future of Japanese encephalitis","volume":"15","author":"Erlanger","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e51027","DOI":"10.7554\/eLife.51027","article-title":"Estimates of the global burden of Japanese encephalitis and the impact of vaccination from 2000\u20132015","volume":"9","author":"Quan","year":"2020","journal-title":"eLife"},{"key":"ref_19","unstructured":"WHO (2025, September 19). Japanese Encephalitis. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/japanese-encephalitis."},{"key":"ref_20","unstructured":"WHO (2025, July 29). Japanese Encephalitis (JE) Reported Cases and Incidence. Available online: https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/japanese-encephalitis-(je)-reported-cases-and-incidence?CODE=GlobalandYEAR=andADVANCED_GROUPINGS=Middle income."},{"key":"ref_21","unstructured":"Australian Government Department of Health, Disability and Ageing (2025, September 18). Japanese Encephalitis, Available online: https:\/\/www.health.gov.au\/diseases\/japanese-encephalitis."},{"key":"ref_22","first-page":"E99","article-title":"Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO(\u00ae))","volume":"59","author":"Amicizia","year":"2018","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"McArthur, M.A., and Holbrook, M.R. (2011). Japanese Encephalitis Vaccines. J. Bioterror. Biodef., S1.","DOI":"10.4172\/2157-2526.S1-002"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"WHO (2016). Japanese Encephalitis Vaccines: WHO position paper, February 2015\u2014Recommendations. Vaccine, 34, 302\u2013303.","DOI":"10.1016\/j.vaccine.2015.07.057"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pedneo.2019.11.009","article-title":"Recommendations for the use of Japanese encephalitis vaccines","volume":"61","author":"Lee","year":"2020","journal-title":"Pediatr. Neonatol."},{"key":"ref_26","unstructured":"Australian Government Department of Health and Aged Care (2025, September 21). Table. Recommended Doses of Japanese Encephalitis Vaccines. Australian Immunisation Handbook, Available online: https:\/\/immunisationhandbook.health.gov.au\/resources\/tables\/table-recommended-doses-of-japanese-encephalitis-vaccines."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcma.2014.12.009","article-title":"Current recommendations for the Japanese encephalitis vaccine","volume":"78","author":"Chen","year":"2015","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_28","unstructured":"GAVI (2025, August 05). How Sri Lanka\u2019s Immunisation System\u2014One of the Region\u2019s Strongest\u2014Is Weathering an Economic Crisis. Available online: https:\/\/www.gavi.org\/vaccineswork\/how-sri-lankas-immunisation-system-one-regions-strongest-weathering-economic-crisis#:~:text=healthcare system develop.-,Gavi\u2019s contributions%2C in particular%2C have included support for health system,smoothly without any."},{"key":"ref_29","unstructured":"GAVI (2025, August 05). Japanese Encephalitis Vaccine Support. Available online: https:\/\/www.gavi.org\/types-support\/vaccine-support\/japanese-encephalitis#:~:text=Gavi\u2019s impact,learned and integrate when possible."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Branda, F., Ali, A.Y., Ceccarelli, G., Albanese, M., Binetti, E., Giovanetti, M., Ciccozzi, M., and Scarpa, F. (2025). Assessing the Burden of Neglected Tropical Diseases in Low-Income Communities: Challenges and Solutions. Viruses, 17.","DOI":"10.3390\/v17030302"},{"key":"ref_31","first-page":"101559","article-title":"Opportunities and challenges of conducting vaccine research in low and middle-income countries in the Asia\u2013Pacific region: Perspectives from the Asia\u2013Pacific Vaccine Research Network","volume":"58","author":"Thobari","year":"2025","journal-title":"Lancet Reg. Health West Pac."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10654-022-00911-3","article-title":"Estimating conditional vaccine effectiveness","volume":"37","author":"Ioannidis","year":"2022","journal-title":"Eur. J. Epidemiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Vaseeharan, B., and Jesudhasan, P. (2025). Chapter 1\u2014Vaccine: History, evolution, and characteristic features in the aquaculture industry. Vaccines in Aquaculture, Academic Press.","DOI":"10.1016\/B978-0-443-22167-5.00013-7"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e19095","DOI":"10.1097\/MD.0000000000019095","article-title":"Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis","volume":"99","author":"Yang","year":"2020","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2016.05.005","article-title":"Towards Predicting Protective Vaccine Responses in the Very Young","volume":"37","author":"Kollmann","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ngwe Tun, M.M., Kyaw, A.K., Nwe, K.M., Inoue, S., Thant, K.Z., and Morita, K. (2021). Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar. Vaccines, 9.","DOI":"10.3390\/vaccines9060568"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100143","DOI":"10.1016\/j.jvacx.2022.100143","article-title":"Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial","volume":"10","author":"Zaman","year":"2022","journal-title":"Vaccine X"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1016\/j.vaccine.2016.10.028","article-title":"Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine","volume":"34","author":"Wijesinghe","year":"2016","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.vaccine.2014.06.036","article-title":"Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka","volume":"32","author":"Wijesinghe","year":"2014","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1016\/j.vaccine.2016.09.005","article-title":"Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children","volume":"34","author":"Janewongwirot","year":"2016","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100074","DOI":"10.1016\/j.jvacx.2020.100074","article-title":"Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9\u201312 months of age in the Philippines: A non-inferiority Phase 4 random","volume":"6","author":"Capeding","year":"2020","journal-title":"Vaccine X"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4161\/hv.20071","article-title":"Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12\u201318 months: Randomized, controlled phase 3 immunogenicity and safety trial","volume":"8","author":"Feroldi","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/21645515.2017.1414763","article-title":"Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children","volume":"14","author":"Chanthavanich","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1016\/j.vaccine.2010.02.108","article-title":"A comparative study of the serological response to Japanese encephalitis vaccine in HIV-infected and uninfected Thai children","volume":"28","author":"Chokephaibulkit","year":"2010","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/infdis\/jiz672","article-title":"Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine","volume":"222","author":"Vadrevu","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Marks, F., Nguyen, T.T.Y., Tran, N.D., Nguyen, M.H., Vu, H.H., Meyer, C.G., You, Y.A., Konings, F., Liu, W., and Wierzba, T.F. (2012). Effectiveness of the Viet Nam produced, mouse brain-derived, inactivated Japanese encephalitis vaccine in Northern Viet Nam. PLoS Neglected Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001952"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO\u00ae (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Schuller","year":"2010","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"886","DOI":"10.4103\/ijmr.IJMR_712_15","article-title":"Immunogenicity & safety of a single dose of live-attenuated Japanese encephalitis vaccine SA 14-14-2 in adults","volume":"144","author":"Khan","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijid.2017.10.010","article-title":"Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study","volume":"66","author":"Vu","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2008.02.042","article-title":"Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants","volume":"26","author":"Gatchalian","year":"2008","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"MacKechnie, G.P.D., Dalton, M., Delport, D., and Vaccher, S. (2025). Using Measles Outbreaks to Identify Under-Resourced Health Systems in Low- and Middle-Income Countries: A Predictive Model. Vaccines, 13.","DOI":"10.20944\/preprints202502.0304.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.vaccine.2016.11.062","article-title":"Post-licensure, phase I.V.; safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand","volume":"35","author":"Chotpitayasunondh","year":"2017","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: Randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum. Vaccines"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/21645515.2014.983412","article-title":"Product review on the JE vaccine IXIARO","volume":"11","author":"Firbas","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hills, S.L., Soeung, S.C., Sarath, S., Morn, C., Dara, C., Fischer, M., and Thigpen, M.C. (2022). An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0269480"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4038\/cmj.v61i3.8344","article-title":"Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 months in National Immunisation Programme of Sri Lanka","volume":"61","author":"Sanchayan","year":"2016","journal-title":"Ceylon Med. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2019.1688032","article-title":"Co-administration of vaccines: A focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines","volume":"16","author":"Bonanni","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_59","unstructured":"Health Technology Assessment Republic of the Philippines (2024). Japanese Encephalitis (JE) Vaccine for children 9 months to 59 months old (Reclassified aHTA), Health Technology Assessment Philippines."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.vaccine.2014.11.046","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012","volume":"33","author":"Rabe","year":"2015","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.jvacx.2022.100179","article-title":"Expanding japanese encephalitis vaccination to selected endemic indonesia provinces: A cost-effectiveness analysis","volume":"11","author":"Kosen","year":"2022","journal-title":"Vaccine X"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1016\/j.vaccine.2008.06.050","article-title":"Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia","volume":"26","author":"Liu","year":"2008","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1016\/j.vaccine.2023.10.007","article-title":"Cost-effectiveness analysis of Japanese Encephalitis (JE) vaccination program in Bali Province, Indonesia","volume":"41","author":"Putri","year":"2023","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3201\/eid3012.231657","article-title":"Cost-effectiveness Analysis of Japanese Encephalitis Vaccination for Children <15 Years of Age, Bangladesh","volume":"30","author":"Nguyen","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.vaccine.2020.02.018","article-title":"Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies","volume":"38","author":"Vodicka","year":"2020","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0972-9062.130153","article-title":"Economic evaluation of Japanese encephalitis vaccination programme in Uttar Pradesh, India: A cost-benefit study","volume":"51","author":"Singh","year":"2014","journal-title":"J. Vector Borne Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1016\/j.vaccine.2010.04.086","article-title":"A cost\u2013effectiveness analysis of Japanese encephalitis vaccine in Cambodia","volume":"28","author":"Touch","year":"2010","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1080\/21645515.2017.1285472","article-title":"Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease","volume":"13","author":"Hegde","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_69","unstructured":"WHO (2019). WHO Guide for Standardization of Economic Evaluations of Immunization Programmes, WHO. [2nd ed.]."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1016\/j.vaccine.2006.04.006","article-title":"Immunization against Japanese encephalitis in China: A policy analysis","volume":"24","author":"Liu","year":"2006","journal-title":"Vaccine"},{"key":"ref_71","unstructured":"Australian Government Department of Health and Aged Care (2025). Japanese Encephalitis, Australian Government Department of Health and Aged Care."},{"key":"ref_72","unstructured":"WHO (2010). Fourth Biregional Meeting on the Control of Japanese Encephalitis (JE), WHO."},{"key":"ref_73","unstructured":"ThinkWell (2020). Immunization Delivery Costs in Low- and Middle-Income Countries, ThinkWell."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1467-842X.2005.tb00747.x","article-title":"An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait","volume":"29","author":"Hanna","year":"2005","journal-title":"Aust. N. Z. J. Public Health"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"taaf006","DOI":"10.1093\/jtm\/taaf006","article-title":"Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults","volume":"32","author":"Mills","year":"2025","journal-title":"J. Travel Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e054219","DOI":"10.1136\/bmjopen-2021-054219","article-title":"Priority setting of vaccine introduction in Bangladesh: A multicriteria decision analysis study","volume":"12","author":"Haider","year":"2022","journal-title":"BMJ Open"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1038\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:48:28Z","timestamp":1760071708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":76,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["vaccines13101038"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13101038","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}